oral Propranolol — Competitive Intelligence Brief

oral Propranolol (oral Propranolol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-selective beta-adrenergic antagonist (beta-blocker). Area: Cardiovascular.

marketed Non-selective beta-adrenergic antagonist (beta-blocker) Beta-1 and beta-2 adrenergic receptors Cardiovascular Small molecule

Target snapshot

oral Propranolol (oral Propranolol) — Ahmed talaat ahmed aly. Propranolol is a non-selective beta-adrenergic receptor antagonist that blocks the effects of epinephrine and norepinephrine on the heart and blood vessels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
oral Propranolol TARGET	oral Propranolol	Ahmed talaat ahmed aly	marketed	Non-selective beta-adrenergic antagonist (beta-blocker)	Beta-1 and beta-2 adrenergic receptors
betablocker titration	betablocker titration	Policlinico Casilino ASL RMB	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
topical Timolol maleate 0.5% eye drops	topical Timolol maleate 0.5% eye drops	Ain Shams University	marketed	Beta-adrenergic antagonist (non-selective)	Beta-1 and beta-2 adrenergic receptors
amiodarone beta blocker sotalol	amiodarone beta blocker sotalol	Connolly, Stuart, M.D.	marketed	Beta-blocker with Class III antiarrhythmic activity	Beta-1 and beta-2 adrenergic receptors; potassium channels (IKr)
Dorzolamide-timolol and latanoprost	Dorzolamide-timolol and latanoprost	Laboratorios Sophia S.A de C.V.	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog	Carbonic anhydrase II (dorzolamide), beta-1 and beta-2 adrenergic receptors (timolol), prostaglandin F receptor (latanoprost)
tafluprost and dorzolamide/timolol	tafluprost and dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analogue / carbonic anhydrase inhibitor / beta-blocker combination	Prostaglandin F receptor (FP receptor), carbonic anhydrase II, beta-1 and beta-2 adrenergic receptors
treatment with brimonidine/timolol	treatment with brimonidine/timolol	Aristotle University Of Thessaloniki	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-selective beta-adrenergic antagonist (beta-blocker) class)

1. Ahmed talaat ahmed aly · 1 drug in this class